Primerica
Primerica's revenue rose 6.6% to $3.3 billion in fiscal 2025. Its net margin was 22.8%, up from 15.2% a year earlier. It paid out $586 million in dividends and buybacks. The diluted share count fell 4.4%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What Primerica does
Primerica sells financial products to middle-income households in the United States and Canada. It does this through a large force of independent sales representatives, who are licensed to sell life insurance and number 151,524. They help clients buy term life insurance, which Primerica itself underwrites. They also sell mutual funds, annuities, managed investments and other products, which Primerica distributes mainly for other companies.
It has three segments. Term Life Insurance earns premiums from policies written by its insurance companies. Investment and Savings Products earns commissions and fees on sales and on client assets, along with recordkeeping and custodian fees. Corporate and Other Distributed Products covers the rest, including products it distributes for others. It sold its Senior Health business in 2024.
Primerica says its annuity and investment products compete with those of many other companies. Its sales representatives are independent contractors, not employees. The company had 2,833 employees at the end of 2025. It became a public company in 2010 after Citigroup transferred the business to it.
Its biggest risks, as it describes them
- Failing to recruit and keep licensed independent sales representatives.
- Laws that could force changes to its independent contractor sales model, or reclassify its representatives as employees.
- Claims experience on its life insurance business that turns out worse than it expected.
- Insurance and securities regulation, and the risk that representatives break the rules.
- Losing or changing its relationships with the fund and annuity companies whose products it sells.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 19.6% a year and net income 14.7% a year, as buybacks cut the share count by 31%.
Returns on capital
Cash flow
Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Primerica's filings doesn't give both for any year, so free cash flow is left out.
Payouts and share count
Valuation
Two ways to value Primerica yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Primerica's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Primerica's cash from operations minus depreciation in fiscal 2025 (free cash flow before spending to grow, as its free cash flow was not available) of $882M, net cash of $160M at December 31, 2025 and 33 million diluted shares, from its filings. The scenarios are fitted to Primerica: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 7.4% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 8%: 7% for a stable business (Life & Health Insurance), plus 1 point as a smaller company, worth $8.6B; the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $276.79
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Primerica's earnings per share of $24.89 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 13.8×, the middle of Primerica's own P/E today, its peers' median and its sector's median (the Financials median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 9%, 8% and 7%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $276.79
- Value at this multiple, against the last close
- —
- Primerica's P/E at the last close
- 11.1×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| UnumUNM | $90.12 | $4.29 | 21.0× |
| CNO Financial GroupCNO | $54.20 | $2.91 | 18.6× |
| PrimericaPRI | $276.79 | $24.89 | 11.1× |
| Globe LifeGL | $156.82 | $15.07 | 10.4× |
| Brighthouse FinancialBHF | $44.83 | $12.53 | 3.6× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 478 | 559 | 594 | 688 | 756 |
| Debt incl. finance leases | 593 | 594 | 594 | 596 | 596 |
| Net debt (negative means net cash) | 115 | 35 | −0 | −92 | −160 |
| Net debt to EBITDA | 0.2x | 0.0x | −0.0x | −0.1x | −0.2x |
| Debt to equity | 0.6x | 0.3x | 0.3x | 0.3x | 0.2x |
| Interest coverage | 22.0x | 27.4x | 30.0x | 39.8x | 43.2x |
| Current ratio | — | — | — | — | — |
| Quick ratio | — | — | — | — | — |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Primerica shares on the open market, and 5 insiders sold $4.5 million, $4.2 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Peter W. SchneiderPresident | Sold plan | 1,800 | $312.65 | $562,770 | Form 4 |
| Aug 11, 2026 | Amber Lynne CottleDirector | Sold | 279 | $313.63 | $87,503 | Form 4 |
| Aug 10, 2026 | Glenn J. WilliamsChief Executive Officer, Director | Sold plan | 1,500 | $320.20 | $480,300 | Form 4 |
| Jun 12, 2026 | Glenn J. WilliamsChief Executive Officer, Director | Sold plan | 1,500 | $280.49 | $420,735 | Form 4 |
| May 18, 2026 | Peter W. SchneiderPresident | Sold plan | 1,800 | $279.64 | $503,352 | Form 4 |
| Mar 10, 2026 | Peter W. SchneiderPresident | Sold plan | 1,800 | $252.38 | $454,284 | Form 4 |
| Mar 2, 2026 | Nicholas Adam JendusaPrincipal Accounting Officer | Sold | 190 | $255.51 | $48,547 | Form 4 |
| Feb 17, 2026 | Glenn J. WilliamsChief Executive Officer, Director | Sold plan | 2,500 | $256.41 | $641,025 | Form 4 |
| Dec 3, 2025 | Joel M. BabbitDirector | Sold | 700 | $255.00 | $178,500 | Form 4 |
| Nov 17, 2025 | Peter W. SchneiderPresident | Sold plan | 2,000 | $255.30 | $510,600 | Form 4 |
| Nov 12, 2025 | Glenn J. WilliamsChief Executive Officer, Director | Sold plan | 2,500 | $259.65 | $649,125 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | — | — | — |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
| Accruals ratio | −0.8% | −2.6% | −1.0% |
Compare
Put Primerica side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Primerica | FY25 | 6.6% | — | — | 34.5% | −0.2x | — | |
| CNO Financial Group | FY25 | 0.8% | 12.3% | — | — | — | — | Compare |
| Globe Life | FY25 | 3.7% | — | 20.9% | 16.0% | 1.4x | — | Compare |
| Brighthouse Financial | FY25 | 43.2% | — | — | — | — | — | Compare |
| Unum | FY25 | 1.5% | — | 4.2% | 7.6% | 0.5x | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1,519 | 1,689 | 1,900 | 2,052 | 2,218 | 2,710 | 2,658 | 2,748 | 3,089 | 3,292 |
| Revenue growth | 8.2% | 11.2% | 12.5% | 8.0% | 8.0% | 22.2% | −1.9% | 3.4% | 12.4% | 6.6% |
| Gross profit | — | — | — | — | — | 2,657 | 2,589 | 2,693 | — | — |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | 219 | 350 | 324 | 366 | 386 | 477 | 472 | 577 | 470 | 751 |
| Diluted EPS (US$) | 4.59 | 7.61 | 7.33 | 8.62 | 9.57 | 11.99 | 12.33 | 15.94 | 13.71 | 22.91 |
| Diluted shares (millions) | 48 | 46 | 44 | 42 | 40 | 40 | 38 | 36 | 34 | 33 |
| Cash flow | ||||||||||
| Cash from operations | 294 | 392 | 478 | 486 | 643 | 657 | 758 | 692 | 862 | 901 |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | 33 | 36 | 44 | 58 | 64 | 75 | 84 | 94 | 113 | 136 |
| Share buybacks | 150 | 150 | 210 | 225 | 231 | 19 | 356 | 375 | 425 | 450 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 494 | 4 | 0 | 0 | 0 |
| Stock-based compensation | 13 | 15 | 17 | 18 | 19 | 17 | 22 | 19 | 25 | 25 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 212 | 280 | 270 | 257 | 548 | 478 | 559 | 594 | 688 | 756 |
| Debt incl. finance leases | 373 | 373 | 374 | 375 | 375 | 593 | 594 | 594 | 596 | 596 |
| Total assets | 11,439 | 12,461 | 12,595 | 13,688 | 14,905 | 16,196 | 14,641 | 15,028 | 14,582 | 15,012 |
| Total liabilities | 10,218 | 11,042 | 11,134 | 12,036 | 13,069 | 14,033 | 12,610 | 12,962 | 12,323 | 12,566 |
| Shareholders' equity | 1,221 | 1,419 | 1,462 | 1,652 | 1,836 | 925 | 2,031 | 2,066 | 2,259 | 2,446 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | 98.0% | 97.4% | 98.0% | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | 14.4% | 20.7% | 17.1% | 17.9% | 17.4% | 17.6% | 17.8% | 21.0% | 15.2% | 22.8% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Return on capital | 17.3% | 26.0% | 22.5% | 23.3% | 23.8% | — | 37.1% | 29.6% | 34.9% | 34.5% |
| Return on equity | 18.5% | 26.5% | 22.5% | 23.5% | 22.1% | 34.6% | 31.9% | 28.1% | 21.8% | 31.9% |
| Return on assets | 2.0% | 2.9% | 2.6% | 2.8% | 2.7% | 3.1% | 3.1% | 3.9% | 3.2% | 5.1% |
| Net debt to EBITDA | 0.4x | 0.2x | 0.2x | 0.2x | −0.3x | 0.2x | 0.0x | −0.0x | −0.1x | −0.2x |